Table 1.
Groups | ||
PS | ILD | |
N. of subjects | 10 | 9 |
Age, years (mean±SD) | 57±10 | 64±11 |
Sex F/M | 4F/6M | 3F/6M |
Clinical diagnosis | Sarcoidosis | Interstitial lung diseases |
FVC % (range; mean±SD) | 71-98; 94.2±15.6 | 42-88; 63.8±28.8 |
DLCO % (range; mean±SD) | 25-85; 66.7±17.5 | 34-75; 54.3±15 |
Recent infections | 0/10 | 0/9 |
Probiotics assumption | 0/10 | 0/9 |
Immunosuppressive therapy (N) | 1/10 | 0/9 |
Corticosteroid therapy (N) | 2/10 | 1/9 |
PS, pulmonary sarcoidosis patients; ILD, interstitial lung diseases; SD, standard deviation; F, female; M, male; FVC, forced vital capacity; DLCO, diffusing capacity of the lung carbon monoxide; N, number